Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Dermatology

Beyond the Skin: Heart and Joint Health in Psoriasis

At a Glance

Psoriasis is a systemic inflammatory disease that affects more than just your skin. The chronic inflammation that causes skin plaques can also increase your risk for heart disease, metabolic syndrome, and psoriatic arthritis. Treating psoriasis early may help protect your long-term health.

Psoriasis is much more than a skin condition; it is a systemic (body-wide) inflammatory disease. For years, the skin was seen as the primary problem, but we now know that the same inflammatory “fire” that causes plaques on your skin can also affect your blood vessels, your metabolism, and your joints [1][2]. This chain reaction is often referred to as the psoriatic march.

The ‘Psoriatic March’ to Heart Disease

The psoriatic march describes how chronic inflammation starts in the skin and “marches” through the rest of the body [1].

  • Systemic Inflammation: Inflammatory proteins (cytokines) produced in psoriatic skin travel through your bloodstream [3].
  • Vascular Impact: These proteins can cause atherosclerosis (inflammation and hardening of the arteries), which increases the risk of heart attacks and strokes [4][5].
  • Metabolic Syndrome: Psoriasis is closely linked to metabolic syndrome, a cluster of conditions including obesity, high blood pressure, and type 2 diabetes [6]. Together, these factors can significantly increase the risk of cardiovascular disease [7].

Psoriatic Arthritis (PsA): The Joint Connection

Approximately 1 in 4 people with psoriasis will eventually develop psoriatic arthritis (PsA) [8]. In the vast majority of cases (about 75-80%), the skin symptoms appear years before the joint pain begins, which gives you and your doctor a vital “head start” for prevention [9].

Early Warning Signs of PsA

Early detection is critical to prevent permanent joint damage. Look out for these three “red flags”:

  1. Dactylitis: A finger or toe that swells up so much it looks like a “sausage” [10].
  2. Enthesitis: Pain at the points where tendons or ligaments attach to your bones, most commonly at the back of the heel (Achilles tendon) or the bottom of the foot [11].
  3. Morning Stiffness: Feeling stiff for more than 30 minutes after waking up, which typically improves once you start moving [12].

If you notice any of these red flags, tell your dermatologist immediately so you can be referred to a rheumatologist.

Can Treatment Protect Your Whole Body?

The most empowering news is that treating psoriasis effectively may do more than just clear your skin—it may actually slow down or interrupt the “march.”

  • Reducing the Risk: Recent evidence suggests that systemic treatments, specifically biologics that target IL-17 or IL-23, can reduce markers of body-wide inflammation [13].
  • Protecting the Heart: Some studies have shown that these therapies may help reduce inflammation in the walls of the arteries and improve overall metabolic health [2][14].
  • Preventing Joint Damage: Using systemic treatments for moderate-to-severe psoriasis is associated with a lower risk of developing psoriatic arthritis later on [15].
System Affected The Impact Why it Matters
Blood Vessels Inflammation leads to plaque buildup (atherosclerosis) [4]. Increased risk of heart attack or stroke.
Metabolism Higher rates of obesity and insulin resistance [6]. Linked to diabetes and hypertension.
Joints Immune system attacks the joints and tendons [8]. Can lead to permanent joint damage if untreated.

By managing your skin inflammation aggressively, you are not just treating a “rash”—you are taking a vital step toward protecting your heart and your mobility for years to come [1].

Common questions in this guide

Does psoriasis increase my risk for heart disease?
Yes, the chronic inflammation that causes psoriasis plaques can travel through your bloodstream and lead to inflammation in the arteries. This process, often called the psoriatic march, increases the overall risk of heart attacks and strokes.
What are the early warning signs of psoriatic arthritis?
Early signs include severe swelling in a single finger or toe, pain at the back of the heel or bottom of the foot, and morning joint stiffness that lasts longer than 30 minutes. If you notice these red flags, you should inform your dermatologist immediately.
How is psoriasis related to metabolic syndrome?
Psoriasis is closely connected to metabolic syndrome, which is a cluster of health conditions that includes obesity, high blood pressure, and type 2 diabetes. Having psoriasis and metabolic syndrome together significantly increases the risk of cardiovascular disease.
Can psoriasis treatments protect my heart and joints?
Yes, managing your psoriasis with systemic treatments like biologics can do more than clear your skin. By targeting body-wide inflammation, these medications may help protect arterial health, improve metabolism, and lower the risk of developing permanent joint damage.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does the severity of my psoriasis increase my risk for the 'psoriatic march' toward heart disease?
  2. 2.Based on my family history and current health, how often should we be screening my blood pressure, cholesterol, and blood sugar?
  3. 3.Could my [specific pain, e.g., heel or finger pain] be an early sign of psoriatic arthritis (PsA)?
  4. 4.Can you use a screening tool like PEST to evaluate my current risk for joint involvement?
  5. 5.Would a systemic treatment (like a biologic) be more effective than topicals at protecting my heart and joints in the long run?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.

    D'Adamio S, Silvaggio D, Lombardo P, et al.

    Expert opinion on drug safety 2019; (18(11)):1031-1041 doi:10.1080/14740338.2019.1663168.

    PMID: 31479282
  2. 2

    Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients.

    Piros ÉA, Szabó Á, Rencz F, et al.

    Life (Basel, Switzerland) 2021; (11(9)) doi:10.3390/life11090919.

    PMID: 34575068
  3. 3

    Keratinocyte-derived IκBζ drives psoriasis and associated systemic inflammation.

    Lorscheid S, Müller A, Löffler J, et al.

    JCI insight 2019; (4(22)).

    PMID: 31622280
  4. 4

    Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities.

    Gisondi P, Bellinato F, Girolomoni G, Albanesi C

    Frontiers in pharmacology 2020; (11()):117 doi:10.3389/fphar.2020.00117.

    PMID: 32161545
  5. 5

    Cardiovascular events risk in patients with systemic autoimmune diseases: a prognostic systematic review and meta-analysis.

    Asenjo-Lobos C, González L, Bulnes JF, et al.

    Clinical research in cardiology : official journal of the German Cardiac Society 2024; (113(2)):246-259 doi:10.1007/s00392-023-02291-4.

    PMID: 37650912
  6. 6

    Unveiling the Metabolic Burden: A Clinicopathological Study of Chronic Plaque Psoriasis and Its Association With Metabolic Syndrome.

    Shah S, Parikh K, Shah ML, Kothari A

    Cureus 2025; (17(8)):e89289 doi:10.7759/cureus.89289.

    PMID: 40909067
  7. 7

    Metabolic Syndrome in Psoriasis Patients-an Observational Study.

    Dascǎlu RC, Bǎrbulescu AL, Dinescu ŞC, et al.

    Current health sciences journal 2024; (50(2)):215-222 doi:10.12865/CHSJ.50.02.06.

    PMID: 39371054
  8. 8

    Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

    Alinaghi F, Calov M, Kristensen LE, et al.

    Journal of the American Academy of Dermatology 2019; (80(1)):251-265.e19 doi:10.1016/j.jaad.2018.06.027.

    PMID: 29928910
  9. 9

    Nail psoriasis as a predictor of the development of psoriatic arthritis.

    Raposo I, Torres T

    Actas dermo-sifiliograficas 2015; (106(6)):452-7.

    PMID: 26026773
  10. 10

    The use of ultrasound to detect enthesitis as a potential guide for intervention in patients with psoriasis at risk of psoriatic arthritis: a systematic review.

    Norden A, Oulee A, Ivanic M, et al.

    International journal of dermatology 2023; (62(8)):973-979 doi:10.1111/ijd.16645.

    PMID: 37005348
  11. 11

    Dactylitis: A hallmark of psoriatic arthritis.

    Kaeley GS, Eder L, Aydin SZ, et al.

    Seminars in arthritis and rheumatism 2018; (48(2)):263-273 doi:10.1016/j.semarthrit.2018.02.002.

    PMID: 29573849
  12. 12

    Prevalence of psoriatic arthritis among patients with plaque psoriasis: a Brazilian retrospective study.

    Gamonal SBL, Gamonal ACC, Brandão MAF, et al.

    Sao Paulo medical journal = Revista paulista de medicina 2021; (139(5)):476-480 doi:10.1590/1516-3180.2020.0629.16032021.

    PMID: 34378736
  13. 13

    The effect of IL-17 and IL-23 ınhibitors on hematological ınflammatory parameters in patients with psoriasis vulgaris.

    Çelik MS, Aktaş H

    Irish journal of medical science 2025; (194(4)):1329-1334 doi:10.1007/s11845-025-03969-6.

    PMID: 40455345
  14. 14

    The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis.

    Jiang W, Li Q, Zheng W

    Archives of dermatological research 2025; (317(1)):643 doi:10.1007/s00403-025-04174-2.

    PMID: 40148675
  15. 15

    Impact of Biologic Therapies on the Risk of Progression from Psoriasis to Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies.

    Xie W, Chen T, Chen Y, Xiao S

    American journal of clinical dermatology 2026; doi:10.1007/s40257-026-01065-8.

    PMID: 42579249

This page provides educational information about the systemic health risks associated with psoriasis. It is not intended to replace professional medical advice. Always discuss your symptoms and screening needs with your dermatologist, rheumatologist, or primary care doctor.

Get notified when new evidence is published on psoriasis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.